RE:RE:RE:Sucker born every minute...I'm not convinced yet. There is still some mini-mansion building intended.
all of our expenditures are focussed on driving shareholder value through investment in the development and monetization of Urocidin™, our key Phase 3 bladder cancer program, and on building, through licensing and acquisition, a pipeline of differentiated human therapeutic products that will drive future shareholder value
The work that everyone is praising, as we all know, as every knowledgeable shareholder would know, should have happened more than 5 years ago.
Their news release clearly indicates, that as soon as the VMC is sold, they will start looking for that new pipeline. That is back to square one, without ever completing an effing thing. Let them find a use for the VMC. It is 1/3 rented now, rent out the rest and get some cash flow. It is actually the only tangible asset they have. Urocidin remains pie in the sky. This is the mistake that BNC made over and over again: selling off functional assets to chase pipeline dreams.
Will Berendt repeat it.